Bi-Kui Zhang

Bi-Kui Zhang

Auto-generated profile, based on publicly available information

Bi-Kui Zhang

Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha 410011, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
YZYichang Zhao
Yichang Zhao
JHJingjing Hou
Jingjing Hou
YXYiwen Xiao
Yiwen Xiao
FWFeng Wang
Feng Wang
BZBikui Zhang
Bikui Zhang
MYMiao Yan
Miao Yan
This prospective observational study aimed to clinically describe voriconazole administrations and trough concentrations in patients with Child–Pugh class C and to investigate the variability of trough concentration. A total of 144 voriconazole trough concentrations from 43 Child–Pugh class C patients were analyzed. The majority of patients (62.8%) received adjustments. The repeated measured trough concentration was higher than the first and final ones generally (median, 4.33 vs. 2.99, 3.90 mg/L). Eight patients with ideal initial concentrations later got supratherapeutic with no adjusted daily dose, implying accumulation. There was a significant difference in concentrations among the six groups by daily dose (p = 0.006). The bivariate correlation analysis showed that sex, CYP2C19 genotyping, daily dose, prothrombin time activity, international normalized ratio, platelet, and Model for end-stage liver disease score were significant factors for concentration. Subsequently, the first four factors mentioned above entered into a stepwise multiple linear regression model (variance inflation factor <5), implying that CYP2C19 testing makes sense for precision medicine of Child–Pugh class C cirrhosis patients. The equation fits well and explains the 34.8% variety of concentrations (R2 = 0.348). In conclusion, it needs more cautious administration clinically due to no recommendation for Child–Pugh class C patients in the medication label. The adjustment of the administration regimen should be mainly based on the results of repeated therapeutic drug monitoring.

29 November 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
YZYichang Zhao
Yichang Zhao
CXChenlin Xiao
Chenlin Xiao
JHJingjing Hou
Jingjing Hou
JWJiamin Wu
Jiamin Wu
YXYiwen Xiao
Yiwen Xiao
MYMiao Yan
Miao Yan
Voriconazole (VRZ) is widely used to prevent and treat invasive fungal infections; however, there are a few studies examining the variability and influencing the factors of VRZ plasma concentrations across different clinical departments. This study aimed to evaluate distinction of VRZ concentrations in different clinical departments and provide a reference for its reasonable use. From 1 May 2014 to 31 December 2020, VRZ standard rates and factors affecting the VRZ trough concentration were analyzed, and a multiple linear regression model was constructed. The standard rates of VRZ in most departments were above 60%. A total of 676 patients with 1212 VRZ trough concentrations using a dosing regimen of 200 mg q12h from seven departments were enrolled in the correlation analysis. The concentration distribution varied significantly among different departments (p < 0.001). Fifteen factors, including department, CYP2C19 phenotype, and gender, correlated with VRZ concentration. A multiple linear regression model was established as follows: VRZ trough concentration = 5.195 + 0.049 × age + 0.007 × alanine aminotransferase + 0.010 × total bilirubin − 0.100 × albumin − 0.004 × gamma-glutamyl transferase. According to these indexes, we can predict possible changes in VRZ trough concentration and adjust its dosage precisely and individually.

16 May 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
YZYichang Zhao
Yichang Zhao
CXChenlin Xiao
Chenlin Xiao
JHJingjing Hou
Jingjing Hou
JWJiamin Wu
Jiamin Wu
YXYiwen Xiao
Yiwen Xiao
MYMiao Yan
Miao Yan
This prospective study aimed to explore the determinants of meropenem trough concentration (Ctrough) in patients with bacterial pneumonia and to investigate the association between its concentration and efficacy. From January 2019 to December 2019, patients with pulmonary infections were prospectively enrolled from the intensive care unit. Factors affecting the meropenem trough concentration were analyzed, and a multiple linear regression model was constructed. Logistic regression analyses were used to investigate the relationship between Ctrough and clinical efficacy. A total of 64 patients were enrolled, in whom 210 meropenem concentrations were measured. Of the total, 60.9% (39/64) were considered clinically successful after treatment. Ctrough may increase with increased blood urea nitrogen, albumin, and concomitant antifungal use. By contrast, concentration may decrease with increased endogenous creatinine clearance rate. Six variables, including Ctrough/minimum inhibitory concentration (MIC) > 4, were associated with the efficacy of meropenem. There was an independent correlation between Ctrough/MIC > 4 and efficacy after fully adjusting for confounding factors. Based upon renal function indexes, it is possible to predict changes in meropenem concentration and adjust the dosage precisely and individually. Ctrough/MIC > 4 is a potential instrument to predict successful treatment with meropenem.

1 July 2015
Verified
Journal Article
Closed access
LCLing-Juan Cao
Ling-Juan Cao
MYMiao Yan
Miao Yan
HLHuan-De Li
Huan-De Li
BZBi-Kui Zhang
Bi-Kui Zhang
PFPing-Fei Fang
Ping-Fei Fang

1 December 2014
Verified
Journal Article
Closed access
HGHui Gong
Hui Gong
HLHuan-De Li
Huan-De Li
MYMiao Yan
Miao Yan
BZBi-Kui Zhang
Bi-Kui Zhang
PJPei Jiang
Pei Jiang
YDYang Deng
Yang Deng

1 June 2016 in Int. Journal of Clinical Pharmacology and Therapeutics
Verified
Journal Article
Closed access
ZLZhi-Hua Li
Zhi-Hua Li
YDYang Deng
Yang Deng
HuaLin CaiHuaLin Cai
HuaLin Cai
ZGZhao-Hui Guo
Zhao-Hui Guo
ZHZhen-Yan Hou
Zhen-Yan Hou
BZBi-Kui Zhang
Bi-Kui Zhang
Spironolactone is a potassium-sparing diuretic and is a competitive antagonist of aldosterone, which is widely used in the treatment of primary aldosteronism, essential hypertension, congestive cardiac failure, and various edematous states. The purpose of this study was to compare the pharmacokinetic properties and bioequivalence of the two formulations of spironolactone tablets in healthy Chinese male subjects under fasting and fed condition.